Pegylated recombinant human leptin

Drug Profile

Pegylated recombinant human leptin

Alternative Names: PEG-OB; Pegylated recombinant native human leptin

Latest Information Update: 05 Jul 2006

Price : $50

At a glance

  • Originator Roche
  • Class Obesity therapies; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 05 Jul 2006 No development reported - Clinical-Phase-Unknown for Obesity in USA (SC)
  • 15 Mar 2001 Investigation in Obesity in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top